Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | HTR2B | P41595 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | CCR2 | P41597 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14848186 | 1.00 | KDM1A (0.48) | KDM1AHTR2CHTR2BHTR2ACCR2 | |
| SCHEMBL14829890 | 0.83 | KDM1A (0.49) | KDM1AHTR2CHTR2BHTR2ACCR2 | |
| SCHEMBL14829889 | 0.83 | KDM1A (0.49) | KDM1AHTR2CHTR2BHTR2ACCR2 | |
| SCHEMBL16727084 | 0.74 | KDM1A (0.48) | KDM1AHTR2CHTR2BHTR2ACCR2 | |
| SCHEMBL24496048 | 0.72 | HTR2C (0.50) | KDM1AHTR2CHTR2BHTR2ACCR2 | |
| SCHEMBL15933206 | 0.70 | HTR2C (0.67) | KDM1AHTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL16727086 | 0.68 | KDM1A (0.42) | KDM1AHTR2CHTR2BHTR2ACCR2 | |
| Methylamine SCHEMBL28776714 | 0.67 | HTR2C (0.51) | KDM1AHTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL14305498 | 0.67 | HTR2C (0.48) | KDM1AHTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL30563689 | 0.67 | HTR2A (0.38) | KDM1AHTR2CHTR2ASLC6A4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105376-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105376-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | KDM1A 346/4885HTR2C 1546/4885HTR2B 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.